VivoSeq
Oncology

Relapsed/refractory Diffuse Large B-Cell Lymphoma

5

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Relapsed/Refractory Diffuse Large B-cell Lymphoma is an early-stage landscape with 5 programs across 4 companies. The most active players are Karyopharm Therapeutics Inc, Roche, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karyopharm Therapeutics Inc

3 programs

PreclinicalRoche logo

Roche

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 71% of 7 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Active, not recruiting·KKaryopharm Therapeutics Inc·Preclinical·NCT04442022·501 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)